Trial Profile

A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dengue tetravalent vaccine Takeda (Primary) ; Hepatitis A vaccine (Primary)
Indications Dengue; Hepatitis A
Focus Pharmacodynamics; Registrational
Sponsors Takeda

19 Jan 2023 Results assessing safety and immunogenicity of coadministration of TAK-003 in healthy adults aged 18-60 years living in the UK, published in the Vaccine.
12 Jul 2019 Status changed from active, no longer recruiting to completed.
25 Jun 2019 Planned End Date changed from 11 Jun 2019 to 10 Jul 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com